CD19 and B-cell non-Hodgkin lymphoma: Prior studies of CD19-CAR-T therapy for B cell lymphoma demonstrated elevated TIGIT expression in host T cells at relapse [20], and high TIGIT expression in CD19-CAR-T cells in vivo was linked to greater exhaustion and poorer prognosis [21].